{"nctId":"NCT02526212","briefTitle":"Buprenorphine Group Medical Visits in Primary Care","startDateStruct":{"date":"2017-01-01","type":"ACTUAL"},"conditions":["Opioid-Related Disorders"],"count":18,"armGroups":[{"label":"G-BMT, Buprenorphine","type":"EXPERIMENTAL","interventionNames":["Behavioral: G-BMT","Drug: Buprenorphine"]},{"label":"Treatment as usual, Buprenorphine","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: Treatment as usual","Drug: Buprenorphine"]}],"interventions":[{"name":"G-BMT","otherNames":["Group Buprenorphine Maintenance Treatment (G-BMT)"]},{"name":"Treatment as usual","otherNames":[]},{"name":"Buprenorphine","otherNames":["Buprenorphine Maintenance Treatment (BMT)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Currently receiving BMT at Montefiore community health center (CHC).\n2. Received BMT for 12 or more weeks.\n3. Persistent opioid abuse (positive toxicology for an unprescribed opioid at most recent test or in 50% or more of collected tests in the previous 6 months.)\n4. Fluent in English of Spanish\n\nExclusion Criteria:\n\n1\\) Pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Opioid Abstinence at 8 Weeks","description":"Opioid abstinence will be based on self-reported opioid use in the prior 30 days at the 8 week visit and the results of urine toxicology test at the 8 week visit. Abstinence (yes) will require no self-reported opioid use and negative urine toxicology test for opiates, methadone, and oxycodone.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Were Retained in Buprenorphine Treatment at 3 Months and 6 Months","description":"Retention is defined as having a medical visit or active buprenorphine prescription 12-16 weeks (3 month retention) and 24-28 weeks (6 month retention) after protocol initiation.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Reported Sharing Injection Equipment at 8 Weeks","description":"We used the HIV risk measure from the NIDA Seek, Test, Treat, and Retain for Vulnerable Populations study. Items for sexual risk behavior are from the Women's Health CoOp Baseline Questionnaire. Items for injection risk behavior are from the STTR Criminal Justice instrument. We will report the number of participants reporting sharing of injection equipment at 8 weeks following enrollment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Acceptability (Scale)","description":"Satisfaction with BMT will be measured on a 5-point Likert scale for participants following completion of the intervention. We used 17 items from the Primary Care Buprenorphine Satisfaction Scale. Each item addressed satisfaction with a specific component of buprenorphine treatment, which participants rated on a scale from 1 (very unsatisfied) to 5 (very satisfied). A higher score indicates greater satisfaction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"0.29"},{"groupId":"OG001","value":"4.8","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Feasibility (Percentage of Visits Attended)","description":"Visit adherence will be measured as the number of buprenorphine visits attended divided by the number of buprenorphine visits required per protocol and multiplied by 100 to give a percentage","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}}